Wall Street's top stock picks for 2026: Mizuho’s under-the-radar name that could more than triple in value
Based on its 12-month price target, Mizuho sees shares of Vaxcyte soaring almost 300% from current levels.
TL;DR
- Mizuho sees over 250% upside potential in Vaxcyte (PCVX).
- Vaxcyte's pneumococcal vaccine platform is seen as de-risked following Phase 2 readouts.
- The adult-catered vaccine (VAX-31) shows potential to be best-in-class with broad serotype coverage.
- While infant vaccine data (VAX-24) was imperfect, steps have been taken to mitigate risks and improve future readouts.
- The $8 billion pneumococcal disease vaccine market is growing, with Vaxcyte's competitors lagging in development.